Condition: Malignacy, Hemoglobinopathie · Sponsor: Società Italiana Talassemie ed Emoglobinopatie
The Trial aims to increase the information available on the relevance of tumor pathology in hemoglobinopathies, updating the data relating to hepatocarcinoma and investigating which other tumors are more frequent in patients with hemoglobinopathies. Still, in relation to tumor pathology, the study will evaluate any differences between the different types of hemoglobinopathy and will investigate the association between the appearance of neoplasms and risk factors such as age, sex, iron accumulation markers, history of bone marrow transplant, and others.
This description comes directly from the study's public registry record.
RAFFAELLA ORIGA, MD · 39 070 6095655 · SECONDACASELLA@HOTMAIL.IT
Always discuss trial participation with your own doctor first.
| Azienda Ospedaliera Universitaria Di Cagliari | Cagliari, Italy | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05286138